You are here
Paul Hackett's Content
1993 Canadian Journal of Psychiatry Risperdal
1993 Canadian Journal of Psychiatry Risperdal
In collections
Metadata (MODS) |
|
|---|---|
| Titles | 1993 Canadian Journal of Psychiatry Risperdal |
| Related Item | |
| Genre | medicine |
| Genre | medicines (psychiatric) |
| Identifier | cjp1993aug_sep_oct_nov_dec7 |
| Note | New. Introducing an important advance in the first-line treatment of schizophrenia. Introducing Risperdal. First-line therapy that brings together the control of both positive and negative symptoms with significantly less EPS. The elusive goal of antipsychotic therapy has always been to curb the symptoms of schizophrenia without encumbering the patient. Too often, subduing the disease has meant subjecting the patient to a disturbed array of side effects. And the ability to control negative symptoms has lagged far behind the control of positive symptoms. Now there is Risperdal. Bringing the proven efficacy and safety profile of a uniquely-balanced serotonin/dopamine antagonist (SDA) to the first-line treatment of schizophrenia. In clinical trials, Risperdal has consistently performed better than haloperidol in controlled positive symptoms and has been dramatically more effective on negative symptoms. Risperdal has demonstrated an excellent tolerability profile, with the most common side effects being insomnia, agitation, anxiety, headahce, and extrapyramidal side effects. However, at optimal dosing, these side effects, including EPS, are virtually the same as placebo. Risperdal. A new class of antipsychotic (SDA) that provides both positive and negative symptoms control with significantly less EPS. Uniquely-balanced serotonin/dopamine antagonism. New Risperdal Positive and negative symptoms control with significantly less EPS. Risperdal first-line therapy that can be the first step in helping to reconstruct the life shattered by schizophrenia. Advantages for patients with schizophrenia, in comparison to haloperidol: greater success in treating positive symptoms, proven success in treating negative symptoms, significantly fewer extrapyramidal side effects (EPS), improved tolerability helps promote compliance. Risperdal is a novel, uniquely-balanced serotonin/dopamine anatgonist. Which may well explain its greater efficacy and safety over a conventional neuroleptic like haloperidol. With its proven symptoms control, low EPS profile and faster onset of action, Risperdal should be of benefit to a wide range of patients with schizophrenia. As well, its low incidence of EPS can be expected to help promote compliance. And at therapeutic doses, Risperdal has demonstrated a marked reduction in total dyskinesia scores, particularly in patients suffering from pre-existing tardive dyskinesia. Risperdal. First-line therapy that can be the first step in helping to reconstruct the life shattered by schizophrenia. Greater success in treating positive symptoms. Proven success in treating negative symptoms. Extrapyramidal side effects at optimal dosing similar to placebo. |
| Abstract | Risperidone, Janssen, A women's face is pictured multiple times. First, she is black and white, negative expression, face broken in half. Then she is pictured in colour, face back together, neutral expression, surrounded by green and yellow thick lines (drug logo). |